Visiting original passage: The Risks of Foreign Investment in U.S. Life Sciences Companies — Why Founders Should Take Heed
The Risks of Foreign Investment in U.S. Life Sciences Companies — Why Founders Should Take Heed
Matt Emma •
In recent years, Chinese investment in U.S. and global biotech and medtech has increased significantly. These partnerships can serve as strategic footholds, raising complex questions around security, sovereignty, and long-term strategy.
